GB201522309D0 - Use - Google Patents

Use

Info

Publication number
GB201522309D0
GB201522309D0 GBGB1522309.2A GB201522309A GB201522309D0 GB 201522309 D0 GB201522309 D0 GB 201522309D0 GB 201522309 A GB201522309 A GB 201522309A GB 201522309 D0 GB201522309 D0 GB 201522309D0
Authority
GB
United Kingdom
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1522309.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Photocure ASA
Original Assignee
Photocure ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Photocure ASA filed Critical Photocure ASA
Priority to GBGB1522309.2A priority Critical patent/GB201522309D0/en
Publication of GB201522309D0 publication Critical patent/GB201522309D0/en
Priority to BR112018012009-0A priority patent/BR112018012009B1/pt
Priority to AU2016372573A priority patent/AU2016372573B2/en
Priority to US16/063,185 priority patent/US10556010B2/en
Priority to FIEP16819894.3T priority patent/FI3389717T3/fi
Priority to EP16819894.3A priority patent/EP3389717B9/en
Priority to PL16819894.3T priority patent/PL3389717T3/pl
Priority to CA3008551A priority patent/CA3008551C/en
Priority to JP2018531667A priority patent/JP6926086B2/ja
Priority to RU2018124868A priority patent/RU2783177C2/ru
Priority to DK16819894.3T priority patent/DK3389717T3/da
Priority to ES16819894T priority patent/ES3015668T3/es
Priority to CN202411498667.9A priority patent/CN119345359A/zh
Priority to PCT/EP2016/081803 priority patent/WO2017103283A1/en
Priority to CN201680079674.2A priority patent/CN108601836A/zh
Priority to KR1020187020006A priority patent/KR102787188B1/ko
Priority to US16/748,332 priority patent/US11311620B2/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/00615-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N5/0613Apparatus adapted for a specific treatment
    • A61N5/062Photodynamic therapy, i.e. excitation of an agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N5/0601Apparatus for use inside the body
    • A61N5/0603Apparatus for use inside the body for treatment of body cavities
    • A61N2005/061Bladder and/or urethra
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N2005/0626Monitoring, verifying, controlling systems and methods
    • A61N2005/0629Sequential activation of light sources
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N2005/0658Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662Visible light
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N2005/0658Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662Visible light
    • A61N2005/0663Coloured light
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB1522309.2A 2015-12-17 2015-12-17 Use Ceased GB201522309D0 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
GBGB1522309.2A GB201522309D0 (en) 2015-12-17 2015-12-17 Use
KR1020187020006A KR102787188B1 (ko) 2015-12-17 2016-12-19 방광암에 대한 신보조 요법
JP2018531667A JP6926086B2 (ja) 2015-12-17 2016-12-19 膀胱癌のための術前補助療法
DK16819894.3T DK3389717T3 (da) 2015-12-17 2016-12-19 Neoadjuvansterapi for blærekræft
US16/063,185 US10556010B2 (en) 2015-12-17 2016-12-19 Neoadjuvant therapy for bladder cancer
FIEP16819894.3T FI3389717T3 (fi) 2015-12-17 2016-12-19 Neoadjuvanttihoito virtsarakon syöpää varten
EP16819894.3A EP3389717B9 (en) 2015-12-17 2016-12-19 Neoadjuvant therapy for bladder cancer
PL16819894.3T PL3389717T3 (pl) 2015-12-17 2016-12-19 Terapia neoadjuwantowa raka pęcherza moczowego
CA3008551A CA3008551C (en) 2015-12-17 2016-12-19 Neoadjuvant therapy for bladder cancer
BR112018012009-0A BR112018012009B1 (pt) 2015-12-17 2016-12-19 Uso de hexil 5-ala éster (hal) ou um sal farmaceuticamente aceitável do mesmo
RU2018124868A RU2783177C2 (ru) 2015-12-17 2016-12-19 Неоадъювантная терапия для рака мочевого пузыря
AU2016372573A AU2016372573B2 (en) 2015-12-17 2016-12-19 Neoadjuvant therapy for bladder cancer
ES16819894T ES3015668T3 (en) 2015-12-17 2016-12-19 Neoadjuvant therapy for bladder cancer
CN202411498667.9A CN119345359A (zh) 2015-12-17 2016-12-19 用于膀胱癌的新辅助疗法
PCT/EP2016/081803 WO2017103283A1 (en) 2015-12-17 2016-12-19 Neoadjuvant therapy for bladder cancer
CN201680079674.2A CN108601836A (zh) 2015-12-17 2016-12-19 用于膀胱癌的新辅助疗法
US16/748,332 US11311620B2 (en) 2015-12-17 2020-01-21 Neoadjuvant therapy for bladder cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1522309.2A GB201522309D0 (en) 2015-12-17 2015-12-17 Use

Publications (1)

Publication Number Publication Date
GB201522309D0 true GB201522309D0 (en) 2016-02-03

Family

ID=55311159

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1522309.2A Ceased GB201522309D0 (en) 2015-12-17 2015-12-17 Use

Country Status (13)

Country Link
US (2) US10556010B2 (enExample)
EP (1) EP3389717B9 (enExample)
JP (1) JP6926086B2 (enExample)
KR (1) KR102787188B1 (enExample)
CN (2) CN119345359A (enExample)
AU (1) AU2016372573B2 (enExample)
BR (1) BR112018012009B1 (enExample)
DK (1) DK3389717T3 (enExample)
ES (1) ES3015668T3 (enExample)
FI (1) FI3389717T3 (enExample)
GB (1) GB201522309D0 (enExample)
PL (1) PL3389717T3 (enExample)
WO (1) WO2017103283A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522311D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use
GB201522309D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use
CA3079496C (en) * 2017-12-01 2021-06-01 Sbi Pharmaceuticals Co., Ltd. Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor
KR102441358B1 (ko) 2020-09-14 2022-09-06 주식회사 아파트엔 아파트의 지수화를 통한 아파트 투자 가치 평가 시스템
WO2024184417A1 (en) 2023-03-07 2024-09-12 Photocure Asa Therapy for bladder cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2157424T3 (es) 1995-03-10 2001-08-16 Photocure Asa Esteres de acido 5-aminolevulinico como agentes fotosensibilizantes en fotoquimioterapia.
US7530461B2 (en) * 1995-03-10 2009-05-12 Photocure Asa Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
GB0018528D0 (en) * 2000-07-27 2000-09-13 Photocure Asa Compounds
ATE481985T1 (de) 2002-07-03 2010-10-15 Ono Pharmaceutical Co Immunpotenzierende zusammensetzungen
GB0406917D0 (en) 2004-03-26 2004-04-28 Photocure Asa Compounds
KR101498834B1 (ko) 2005-05-09 2015-03-05 오노 야꾸힝 고교 가부시키가이샤 예정 사멸 인자 1(pd-1)에 대한 인간 모노클로날 항체, 및 항-pd-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
HRP20080053A2 (hr) 2005-07-01 2009-08-31 Medarex Ljudska monoklonska protutijela na ligand 1 za programiranu smrt stanice (pd-l1)
CN104945508B (zh) 2007-06-18 2019-02-22 默沙东有限责任公司 针对人程序性死亡受体pd-1的抗体
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
CA3120172A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
SI2440199T1 (sl) 2009-06-11 2016-05-31 Photocure Asa Poltrdni sestavki in farmacevtski proizvodi
TWI835048B (zh) 2011-08-01 2024-03-11 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
MX349096B (es) 2011-11-28 2017-07-11 Merck Patent Gmbh Anticuerpos anti-pd-l1 y sus usos.
SG10201603055WA (en) 2012-05-31 2016-05-30 Genentech Inc Methods Of Treating Cancer Using PD-L1 Axis Binding Antagonists And VEGF Antagonists
US8927761B2 (en) 2012-06-28 2015-01-06 Photocure Asa Form of hexyl-5-aminolevulinate hydrochloride and methods of using the same
SG11201500805VA (en) * 2012-08-03 2015-02-27 Photocure Asa Compounds
GB201522309D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use
CN109010850B (zh) * 2018-08-01 2021-10-22 上海师范大学 一种负载姜黄素的葡聚糖修饰的钆掺杂的空心介孔二氧化硅纳米材料的制备方法及应用

Also Published As

Publication number Publication date
US10556010B2 (en) 2020-02-11
EP3389717A1 (en) 2018-10-24
EP3389717B1 (en) 2025-02-19
RU2018124868A3 (enExample) 2020-05-13
CN108601836A (zh) 2018-09-28
KR102787188B1 (ko) 2025-03-25
CA3008551A1 (en) 2017-06-22
JP2018537514A (ja) 2018-12-20
BR112018012009A2 (pt) 2018-12-04
US20200155683A1 (en) 2020-05-21
RU2018124868A (ru) 2020-01-27
PL3389717T3 (pl) 2025-06-09
DK3389717T3 (da) 2025-03-31
JP6926086B2 (ja) 2021-08-25
FI3389717T3 (fi) 2025-04-08
AU2016372573A1 (en) 2018-07-12
WO2017103283A1 (en) 2017-06-22
ES3015668T3 (en) 2025-05-07
CN119345359A (zh) 2025-01-24
US20180369379A1 (en) 2018-12-27
US11311620B2 (en) 2022-04-26
EP3389717B9 (en) 2025-07-23
KR20180094987A (ko) 2018-08-24
AU2016372573B2 (en) 2022-07-21
BR112018012009B1 (pt) 2023-12-19

Similar Documents

Publication Publication Date Title
GB201502152D0 (en) Novel use
GB201509585D0 (en) -
GB201500806D0 (en) Aerosol-gnerating aticle
GB201509326D0 (en) Novel use
GB2544748B (en) Microscaffold
GB201522309D0 (en) Use
GB201522311D0 (en) Use
DK3242882T3 (en) Cgrp-antagonistpeptider
GB201521085D0 (en) Use
GB201518466D0 (en) Use
GB201510077D0 (en) Use
GB201516249D0 (en) Liqui-glove
LT3393990T (lt) Peg rišiklis
GB201518831D0 (en) New use
GB201515850D0 (en) Glycommetics
GB201522443D0 (en) Use
GB201522411D0 (en) Use
GB201515987D0 (en) Use
GB201617732D0 (en) Corbel-Pro
GB201520225D0 (en) Novel use
GB201513803D0 (en) Novel Use
GB201510628D0 (en) Novel use
GB201521295D0 (en) iStudent
GB201520415D0 (en) Roadplate
GB201520000D0 (en) Drydam

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)